Oral spironolactone therapy in male patients with rosacea.
Spironolactone at 50 mg/day was orally administered for four weeks to 13 male patients with rosacea in order to observe its clinical effectiveness. Serum estradiol (E2), 17OH-progesterone (17OH-P4), testosterone (T), androstenedione (delta 4 A), dihydrotestosterone (DHT), dehydro-epiandrosterone sulfate (DHEA-S) were measured prior to and after treatment. Although there were no significant changes in T, delta 4A, DHT, or DHEA-S, the serum levels of 17OH-P4 increased significantly. E2 tended to increase, although the change was not significant. Two of the 13 patients discontinued spironolactone treatment because of general malaise, but seven of the remaining eleven patients exhibited an improvement in their rosacea. These findings demonstrate that a low dose of spironolactone is effective in the treatment of rosacea in some male patients and suggest that it is possible that changes in the metabolism of sex steroid hormones such as cytochrome p-450 isozymes have some bearing on the etiology of rosacea.
Aizawa
H
H
Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
Niimura
M
M
D000284:Administration, Oral; D000328:Adult; D012739:Gonadal Steroid Hormones / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D012393:Rosacea / Q000097:blood / Q000188:drug therapy*; D012627:Sebaceous Glands / Q000187:drug effects; D013148:Spironolactone / Q000008:administration & dosage* / Q000494:pharmacology
D012739:Gonadal Steroid Hormones; D013148:Spironolactone